ISMP (US) Français Contact Us Feedback
     Search:  
   
 
 
 
Questionnaire
Education to support mandatory serious ADR and MDI reporting (Vanessa's Law)
 
 
 

ISMP Canada/HSO/CPSI

Background

The Protecting Canadians from Unsafe Drugs Act, also known as Vanessa's Law, will strengthen Health Canada's ability to collect information on drugs and medical devices, and allow it to take quick and appropriate action when a serious health risk is identified.

The Law includes a requirement for mandatory reporting of serious adverse drug reactions (ADR) and medical device incidents (MDI) by hospitals.

An educational approach has been designed to provide core content (in 4 PowerPoint modules) about ADR and MDI reporting that can be used by healthcare leadership, healthcare providers, patients and families, and educators. The modules are intended to be building blocks (either as an individual slide or an entire module) for you to integrate into your own learning or to incorporate into orientation, continuing education and other education activities.

Introduction

Thank you for taking the time to complete this questionnaire. The purpose of this questionnaire is to evaluate the usefulness and your intent to use the education content contained in the modules. Your responses will used to develop the final on-going evaluation and monitoring plan which will be delivered to Health Canada. All responses will be kept confidential.

1. How did you learn about the education modules?

  • Social marketing campaign (Twitter/Facebook/LinkedIn)
  • Media release
  • Website (ISMP Canada/HSO/CPSI)
  • Forums/presentations/webinars
  • Email
  • Colleague/staff
  • Meeting
  • Newsletter/article
  • Other, please explain

2. Were the modules easy to access? (1 - not easy and 5 - very easy)

1 2 3 4 5

3. Which modules did you access? (Check all that apply)

  • Module 1: Overview of Vanessa's Law & Reporting
  • Module 2: Reporting Processes to Health Canada
  • Module 3: Strategies to Promote & Support Mandatory Reporting
  • Module 4: Health Canada's Review & Communication of Safety Findings
  • All

4. From which module(s) will you use all or some of the content (Check all that apply)

  • Module 1: Overview of Vanessa's Law & Reporting
  • Module 2: Reporting Processes to Health Canada
  • Module 3: Strategies to Promote & Support Mandatory Reporting
  • Module 4: Health Canada's Review & Communication of Safety Findings
  • All
  • None

If you answered none, please explain why you will not use.


5. Is the information presented helpful? (1 - not helpful and 5 - very helpful)

1 2 3 4 5

Comments:


6. Based on the content of the modules, do you have a good understanding of the mandatory reporting requirements? (1- low understanding and 5 - strong understanding)

1 2 3 4 5

Comments:


7. Based on the content of the modules, do you have a good understanding of the strategies to promote and support mandatory reporting? (1- low understanding and 5 - strong understanding)

1 2 3 4 5

Comments:


8. Do you think the content of the modules will contribute to improved reporting?

  • Yes
  • No

Comments:


9. How do you plan to use the content from the modules?

  • As self-learning material
  • In an orientation program
  • As a stand-alone educational offering
  • As a component of an e-learning platform or continuing education program
  • In presentations or lectures
  • I will not use the content

Comments:


10. Which modules are you most likely to use?

  • Module 1: Overview of Vanessa's Law & Reporting
  • Module 2: Reporting Processes to Health Canada
  • Module 3: Strategies to Promote & Support Mandatory Reporting
  • Module 4: Health Canada's Review & Communication of Safety Findings
  • All
  • None

Comments:


11. Based on the principle that the best people to communicate information about Vanessa's Law are those closest to their audience, we encourage using some or all of the content depending on your needs.

Will this approach, that allows you to adapt the modules, be helpful to you?

  • Yes
  • No
  • Not applicable (e.g., the materials are for my own learning)

Comments:


12. A) Would you recommend the modules to colleagues?

  • Yes
  • No
  • B) Why or why not?

13. Do you have any recommendations for improving the dissemination of the modules?

  • No
  • Yes, please explain

14. Do you have any additional suggestions on how to use the modules to improve reporting of serious adverse drug reactions and medical device incidents?

  • No
  • Yes, please explain

Demographic

Please review the nine (9) possible respondent categories before making the selection that best represents you or your organization.

I am responding as, or on behalf of, a(n):

+ Consumer/Patient/Caregiver...

Consumer/Patient/Caregiver
Consumer/patient society or organization - please specify

+ Healthcare provider...

Dentist
Medical doctor
Nurse
Pharmacist
Other - please specify profession

+ Non-clinical professional/association...

Engineer, biomedical technician, etc. – please specify
Healthcare manager/executive - please specify type of facility or organization
Safety or risk officer - please specify
Non-clinical association - please specify

+ Association or organization of health professionals...

Dentistry
Medicine
Nursing
Pharmacy
Other - please specify profession

+ Professional regulatory body...

Dentistry
Medicine
Nursing
Pharmacy
Other - please specify profession

+ Healthcare facility or organization/association...

Hospital or health system
Long-term care facility
Other - please specify
Organization representing healthcare facilities - please specify

+ Health and social services provider (excluding hospitals, long-term care facilities, and care homes)...

Community care (e.g., regional home care provider)
Government - please specify, including level of government
Organization representing health and social services providers - please specify

+ Academia...

University/college/faculty (academic institution) - please specify
Organization representing academia - please specify

+ Other...

Other (e.g., pharmaceutical industry, insurer, information technology provider, etc.) - please specify

If you agree to be reached for clarification or additional discussion, please provide your e-mail address:

Copyright © 2000-2020 Institute for Safe Medication Practices Canada (ISMP Canada). All Rights Reserved. Privacy. Disclaimer.